Salbutamol with ipratropium (Duolin) nebuliser: Supply issue

Supply issue Section 29A Active

Due to issues at the manufacturer, the supplier expects to run out of the Duolin nebulisers (Pharmacode: 2039281)

Affected product

Due to issues at the manufacturing plant, the supplier expects to run out of this product:

  • Chemical: Salbutamol 2.5 mg with ipratropium bromide 0.5 mg per vial
  • Presentation: Nebuliser soln, 2.5 ml ampoule
  • Brand: Duolin
  • Pharmacode: 2039281
  • Subsidy: $11.04
  • Measure / Qty: per 20

Schedule listing for Duolin nebulisers(external link)

Alternative listed 1 February 2026

The supplier, Rex Medical, has secured stock of an alternative. This will be listed in the Schedule from 1 February 2026. This medicine has not been approved by Medsafe. It will need to be prescribed and dispensed in line with section 29A of the Medicines Act.

Differences 

  • Cipla S29 is a 30-pack, where Duolin is a 20-pack.
  • Cipla S29 is a 3 ml vial where Duolin is a 2.5 ml ampoule.
  • The vials are labelled "albuterol". This is the American spelling for salbutamol.
  • Albuterol sulfate 3 mg is the same as salbutamol 2.5 mg

Listing details

  • Chemical: Salbutamol 2.5 mg with ipratropium bromide 0.5 mg per vial
  • Presentation: Nebuliser soln, 3 ml vial
  • Brand: Cipla S29
  • Pharmacode: 2719959
  • Subsidy: $16.56
  • Measure / Qty: per 30
  • Section 29 and Wastage apply

Pharmacists, please note that this product expires July 2026.

.
Cipla S29 box labelling

Managing acute severe asthma

The Asthma and Respiratory Foundation has published algorithms for managing acute and severe asthma in adults and children.

NZ Asthma Guidelines | Quick reference guide | Asthma + Respiratory Foundation website [PDF](external link)

Prescribing and supplying an unapproved medicine

Section 29A of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people. However, unapproved medicines cannot be supplied under PSO. 

We know supplying a medicine under section 29A is not ideal. In this case, however, this will allow people to continue to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Advice for prescribing under section 29 – BPAC website(external link) 

Prescriber and pharmacist requirements for section 29 and 29A medicines – Medsafe website(external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)